SCHEMBL20536341

SCHEMBL20536341

Fc1ccc(-c2cc(CBr)no2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.47
RAB9A P51151 7/20 0.47
MAPT P10636 7/20 0.47
NPC1 O15118 6/20 0.47
TP53 P04637 3/20 0.47
HTT P42858 2/20 0.47
TDP1 Q9NUW8 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HDAC6 Q9UBN7 2/20 0.44
PTGS2 P35354 1/20 0.44
CXCR1 P25024 1/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7898072 0.82 PTGS2 (0.48) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL2427499 0.82 NOTUM (0.51) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL29197993 0.82 TDP1 (0.55) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL4060532 0.82 NOTUM (0.70) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL8418866 0.82 MAPT (0.51) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL2431070 0.82 NOTUM (0.70) NOTUMRAB9AMAPTNPC1TP53
SCHEMBL2538472 0.81 NOTUM (0.68) NOTUMRAB9AMAPTNPC1TDP1
SCHEMBL4437276 0.81 EPHX2 (0.48) NOTUMRAB9AMAPTTDP1L3MBTL1
SCHEMBL29197992 0.78 ACKR3 (0.44) TP53
SCHEMBL15009366 0.78 MAPT (0.50) NOTUMRAB9AMAPTNPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117417334-A Azole derivative containing isoxazole structure, and preparation method and application thereof 沈阳药科大学 2024-01-19 CN disclosed
US-20210238187-A1 AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES WILLIAM MARSH RICE UNIVERSITY (US) 2021-08-05 US disclosed
US-20210238187-A1 AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES WILLIAM MARSH RICE UNIVERSITY (US) 2021-08-05 US disclosed
CN-110944664-A Aziridines containing epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates 威廉马歇莱思大学 2020-03-31 CN disclosed
EP-3609538-A1 AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES William Marsh Rice University (US) 2020-02-19 EP disclosed
WO-2018191394-A1 AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES WILLIAM MARSH RICE UNIVERSITY (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238187-A1 AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES EPOR, EZR, CD47 NOTUM 2621/4885RAB9A 108/4885MAPT 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.